Janney Capital Initiates Alnylam Pharmaceuticals At Buy

Analysts at Janney Capital initiated coverage on

with a Buy rating. The target price for Alnylam Pharmaceuticals is set to $139. Alnylam Pharmaceuticals shares have gained 55.06% over the past 52 weeks, while the S&P 500 index has surged 11.16% in the same period. Alnylam Pharmaceuticals' shares rose 2.09% to close at $115.94 yesterday.